Real-world Study Review: Kalydeco Improves Health Outcomes, Quality of Life

Real-world Study Review: Kalydeco Improves Health Outcomes, Quality of Life

294163

Real-world Study Review: Kalydeco Improves Health Outcomes, Quality of Life

A review of 57 real-world studies found that people with cystic fibrosis (CF) who take Kalydeco (ivacaftor) experience improvements in lung function, nutrition, and quality of life (QoL). Reduced healthcare system use, lower Pseudomonas aeruginosa prevalence, fewer organ transplants, and less mortality are other benefits associated with the Vertex Pharmaceuticals therapy. The improvements were reported as early as one month after the start of treatment — and were sustained for up to five years. The…

You must be logged in to read/download the full post.